{"url_path":"/sec/sgmt/8-k/2026-04-27/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-048971-index.html","accession_number":"0001104659-26-048971","cik":"0001400118","ticker":"SGMT","issuer_name":"Sagimet Biosciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-048971-index.html","primary_entity_key":"0001400118","primary_entity_name":"Sagimet Biosciences Inc."},"word_count":95,"has_tables":true,"body_markdown":"**Item 9.01**\n**Financial Statements and Exhibits**\n\n \n\n**(d) Exhibits**\n\n \n\nExhibit \n\nNo.\n \nDocument\n\n[99.1](tm2612738d2_ex99-1.htm)\n \n[Investor Presentation of Sagimet Biosciences Inc., dated April 27, 2026.](tm2612738d2_ex99-1.htm)\n\n[99.2](tm2612738d2_ex99-2.htm)\n \n[Press Release of Sagimet Biosciences Inc., dated April 27, 2026. ](tm2612738d2_ex99-2.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nas amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \nSagimet Biosciences Inc.\n\n \n \n \n\nDate: April 27, 2026\nBy:\n/s/ David Happel\n\n \n \nDavid Happel\n\n \n \nChief Executive Officer"}